Brief: Biosenic: Autoimmune Disease Platform Has Completed Phase IIB Trial

Biosenic SA

08/11/2022 06:13

Nov 8 (Reuters) - Bone Therapeutics SA  BIOS.BR :
    * BIOSENIC PROVIDES UPDATE ON ITS AUTOIMMUNE DISEASE
PLATFORM
BASED ON ATO (ARSENIC TRIOXIDE)
    * AUTOIMMUNE DISEASE PLATFORM HAS COMPLETED SUCCESSFUL PHASE
IIB
TRIAL TARGETING CGVHD (CHRONIC GRAFT VERSUS HOST DISEASE), WITH
DEMONSTRATED EFFICACY OF MORE THAN 75%
    * PHASE III IS UNDER PREPARATION WITH EXPECTED ACCELERATED
EXAMINATION BY FDA

Source text for Eikon:  ID:nGNE6wLLzM 
Further company coverage:  BIOS.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))